Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

elimusertib (BAY 1895344)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Bayer

Drug class:

ATR inhibitor

Related drugs:

DDR	Cervical Cancer	DDR	Cervical Cancer	BAY 1895344 Sensitive: C2 – Inclusion Criteria BAY 1895344 Sensitive : C2	BAY 1895344 Sensitive: C2 – Inclusion Criteria BAY 1895344 Sensitive : C2
ATM deletion	Solid Tumor	ATM deletion	Solid Tumor	BAY 1895344 Sensitive: C2 – Inclusion Criteria BAY 1895344 Sensitive : C2	BAY 1895344 Sensitive: C2 – Inclusion Criteria BAY 1895344 Sensitive : C2
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3
ATM expression + ATM T2333fs* + EGFR negative	HER2 Negative Breast Cancer	ATM expression + ATM T2333fs* + EGFR negative	HER2 Negative Breast Cancer	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3
ATM PI2629fs*	Endometrial Cancer	ATM PI2629fs*	Endometrial Cancer	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3
ATM mutation	Solid Tumor	ATM mutation	Solid Tumor	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3
DDR	Ovarian Cancer	DDR	Ovarian Cancer	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3
FGFR1-G3BP2 fusion	Pancreatic Cancer	FGFR1-G3BP2 fusion	Pancreatic Cancer	BAY 1895344 Resistant: C4 – Case Studies BAY 1895344 Resistant : C4	BAY 1895344 Resistant: C4 – Case Studies BAY 1895344 Resistant : C4
ATRX mutation	Uterine Corpus Leiomyosarcoma	ATRX mutation	Uterine Corpus Leiomyosarcoma	BAY 1895344 Sensitive: D – Preclinical BAY 1895344 Sensitive : D	BAY 1895344 Sensitive: D – Preclinical BAY 1895344 Sensitive : D
TROP2 positive	Triple Negative Breast Cancer	TROP2 positive	Triple Negative Breast Cancer	sacituzumab govitecan-hziy + BAY 1895344 Sensitive: D – Preclinical sacituzumab govitecan-hziy + BAY 1895344 Sensitive : D	sacituzumab govitecan-hziy + BAY 1895344 Sensitive: D – Preclinical sacituzumab govitecan-hziy + BAY 1895344 Sensitive : D
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	sacituzumab govitecan-hziy + BAY 1895344 Sensitive: D – Preclinical sacituzumab govitecan-hziy + BAY 1895344 Sensitive : D	sacituzumab govitecan-hziy + BAY 1895344 Sensitive: D – Preclinical sacituzumab govitecan-hziy + BAY 1895344 Sensitive : D
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	olaparib + fam-trastuzumab deruxtecan-nxki + BAY 1895344 Sensitive: D – Preclinical olaparib + fam-trastuzumab deruxtecan-nxki + BAY 1895344 Sensitive : D	olaparib + fam-trastuzumab deruxtecan-nxki + BAY 1895344 Sensitive: D – Preclinical olaparib + fam-trastuzumab deruxtecan-nxki + BAY 1895344 Sensitive : D
ERBB3 expression	Estrogen Receptor Positive Breast Cancer	ERBB3 expression	Estrogen Receptor Positive Breast Cancer	U3-1402 + BAY 1895344 Sensitive: D – Preclinical U3-1402 + BAY 1895344 Sensitive : D	U3-1402 + BAY 1895344 Sensitive: D – Preclinical U3-1402 + BAY 1895344 Sensitive : D